Additional file 1: Fig. S1. Expression of OXPHOS and glycolysis markers in melanoma xenografts. A-E Immunohistochemical staining of A OXPHOS complex I (CI), B complex II (CII), C complex IV (CIV), D hexokinase 2 (HK2), and E glucose transporter 1 (GLUT1) in A375, WM47, WM3311, and WM3000 tumors from mice fed a control diet. Individual data points and median; n = 5-6; p values were determined by a Kruskal-Wallis test with Dunn's multiple comparisons test; **p20% was a termination criterion. Fig. S5. Beta-hydroxybutyrate and acetoacetate have no effect on proliferation of human melanoma cells in vitro. A-D Treatment of human melanoma cell lines A A375, B WM47, C WM3311, and D WM3000 with 2.5, 5, and 10 mM beta-hydroxybutyrate (BHB), lithium-acetoacetate (LiAcAc) and lithium-chloride (LiCl). p values were determines by a one-way ANOVA with Dunnett's multiple comparisons test; n = 8 from 2 independent experiments. Fig. S6. Tumor growth and body weight of B16-M4b-melanoma bearing syngeneic C57BL/6j mice treated with a control diet or KDs. A-C Tumor growth curves of single B16-M4b melanoma allografts treated with A CTRL, B LCT or C LCT-MCT diet. D-F Body weight curves of single B16-M4b-melanoma bearing mice treated with D CTRL, E LCT or F LCT-MCT diet. Net body weight is shown as % of the initial body weight. Body weight loss >20% was a termination criterion.